Given the pro-tumorigenic role NIK has in cancer and our studies suggesting that upregulation of NIK gene expression by cytokines in the tumor microenvironment can robustly trigger invasion, the inhibition of NIK may prove a promising therapeutic target for primary as well as recurrent, invasive or metastatic tumors22, 38–40. The gene discussed is MAP3K14; the disease is cancer.